Similar companies
Company | Transaction Value | |
---|---|---|
OcugenOCGN |
-$4.6M | |
AmarinAMRN |
$1.7M | |
Gilead SciencesGILD |
-$254M | |
Anavex Life SciencesAVXL |
-$14M | |
Inovio PharmaceuticalsINO |
-$2.2M |
Insider Transactions
Name | Transaction Date | Sold / Bought | Shares | Price | Value |
---|---|---|---|---|---|
Machatha Stephen | Aug 12, 2024 | Sell | 16,041 | $4.7363 | $76,000 |
Greenberg Bruce | Aug 12, 2024 | Sell | 10,834 | $4.7363 | $51,000 |
EDELMAN JOSEPH | Apr 5, 2024 | Buy | 37,712 | $4.74 | $180,000 |
EDELMAN JOSEPH | Apr 4, 2024 | Buy | 140,281 | $4.67 | $660,000 |
EDELMAN JOSEPH | Apr 3, 2024 | Buy | 309,847 | $4.09 | $1.3M |
EDELMAN JOSEPH | Apr 2, 2024 | Buy | 186,051 | $3.44 | $640,000 |
EDELMAN JOSEPH | Apr 1, 2024 | Buy | 8,374 | $3.25 | $27,000 |
Machatha Stephen | Mar 12, 2024 | Sell | 11,537 | $3.164 | $37,000 |
Machatha Stephen | Mar 12, 2024 | Sell | 11,537 | $3.164 | $37,000 |
Brady Todd C | Mar 12, 2024 | Sell | 85,324 | $3.05 | $260,000 |
Greenberg Bruce | Mar 11, 2024 | Sell | 13,201 | $3.4064 | $45,000 |
Greenberg Bruce | Mar 11, 2024 | Sell | 13,201 | $3.4064 | $45,000 |
Machatha Stephen | Mar 11, 2024 | Sell | 18,231 | $3.4064 | $62,000 |
Brady Todd C | Mar 11, 2024 | Sell | 97,914 | $3.2735 | $320,000 |
EDELMAN JOSEPH | Oct 18, 2023 | Sell | 306,499 | $1.74 | $530,000 |
EDELMAN JOSEPH | Oct 16, 2023 | Sell | 2,450,000 | $1.6 | $3.9M |
Miller-Rich Nancy | Apr 12, 2023 | Buy | 509 | $10.13 | $5,200 |
What's the latest insider transaction for Aldeyra Therapeutics?
The most recent insider transaction for Aldeyra Therapeutics was conducted by Machatha Stephen, who sold 16,041 shares on August 12, 2024 at a price of $4.74 per share.
Which insider bought the most ALDX stock over the last two years?
EDELMAN JOSEPH has bought the most ALDX stock in the last 2 years, with a total value of $2.8M.
Which insider has sold the most ALDX stock over the last two years?
EDELMAN JOSEPH has sold the most ALDX stock in the last 2 years, with a total value of $4.5M.
What is the total value of insider transactions for Aldeyra Therapeutics (ALDX) in the last 2 years?
The total value of insider transactions for Aldeyra Therapeutics in the last 2 years is negative, amounting to -$2.6M. This suggests that insiders have predominantly sold shares, which could reflect various personal or financial considerations rather than a straightforward outlook on the company's future performance.
How do insider transactions over the last 2 years reflect on Aldeyra Therapeutics' market confidence?
Over the last 2 years, insider transactions for Aldeyra Therapeutics have largely consisted of selling shares, which could suggest various personal or financial motivations among insiders. The higher number of sales might require investors to investigate further, considering insiders might have insights or reasons not immediately apparent to the public.
Why is monitoring insider trading activity important for investors?
Monitoring insider trading activity is important because it provides insights into the confidence levels of a company's insiders, such as executives and directors, regarding the company's future prospects. Insider buying can signal optimism, suggesting the stock may be undervalued, while insider selling might raise questions about the stock's upcoming performance. However, it's essential to consider that sales can also occur for personal financial reasons. Insider trading activity is a valuable indicator that, when combined with other data, can help inform investment decisions.